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Available online date 10 August 2014Abstract Though expression of the homeobox transcription factor Nanog is generally restricted to pluripotent cells and early
germ cells, many contradictory reports about Nanog's involvement in tumorigenesis exist. To address this, a modified Tet-On
system was utilized to generate Nanog-inducible mice. Following prolonged Nanog expression, phenotypic alterations were found
to be restricted to the intestinal tract, leaving other major organs unaffected. Intestinal and colonic epithelium hyperplasia was
observed—intestinal villi had doubled in length and hyperplastic epithelium outgrowths were seen after 7 days. Increased
proliferation of crypt cells and downregulation of the tumor suppressors Cdx2 and Klf4 was detected. ChIP analysis showed physical
interaction of Nanogwith the Cdx2 and Klf4 promoters, indicating a regulatory conservation fromembryonic development. Despite
downregulation of tumor suppressors and increased proliferation, ectopic Nanog expression did not lead to tumor formation. We
conclude that unlike other pluripotency-related transcription factors, Nanog cannot be considered an oncogene.
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(http://creativecommons.org/licenses/by-nc-nd/3.0/).Oct4, Sox2, and Nanog constitute the core transcriptional
network of pluripotency. Acting together, these genes
regulate self-renewal as well as the early stages of cellular
differentiation both in vivo and in vitro (Boyer et al., 2005;
Wang et al., 2006; Masui et al., 2007). Nanog expression is
restricted to the developing embryo, where it is detectable inn access article under the CC BY-NC-ND license
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in the genital ridge during the formation of germ cells
(Chambers et al., 2003; Mitsui et al., 2003). After birth,
Nanog is undetectable in healthy somatic tissues but has been
reported to be re-expressed in a number of somatic and
germline tumors. There is mounting evidence suggesting that
tumors are driven to grow by a small subfraction of
cancer-inducing stem cells with the ability to initiate and
maintain tumor growth and plasticity (Al-Hajj et al., 2003;
O'Brien et al., 2007; Zhang et al., 2008; Hubbard and Gargett,
2010). Those studies led to investigations into tumor initiation
and stemness, and subsequently to the hypothesis that certain
tumors may arise from undifferentiated stem cells or that
these undifferentiated stem cells undergo spontaneous de-
differentiation to give rise to cancer-inducing cells (Reya et
al., 2001; Beachy et al., 2004; Lobo et al., 2007; Stingl and
Caldas, 2007). Gene expression analysis has recently been
utilized to identify the re-activation of pluripotency-related
markers in different human tumors. These studies have shown
that similar global gene expression patterns in tumors and ES
cells correlates with poorly differentiated andmore aggressive
tumors (Ben-Porath et al., 2008;Wong et al., 2008). Expression
of pluripotency-related transcription factors such as Oct4 and
Nanog has been associatedwith tumorigenesis inmany reports,
but the exact functional involvement of these factors in tumor
progression and/or development has been controversial. For
Oct4, many contradictory studies have been published
depicting its presence or absence in different types of tumors
(Tai et al., 2005; Atlasi et al., 2007; Ben-Porath et al., 2008;
Cantz et al., 2008). However, in 2005 a study by Konrad
Hochedlinger and colleagues finally clarified that Oct4 indeed
has tumorigenic potential and can be considered to be an
oncogene. In that study, the authors showed that ectopic
expression of Oct4 in adult mice led to the formation of
dysplastic lesions in the gut and invasive tumor growth in the
skin (Hochedlinger et al., 2005). As for Oct4, Nanog expression
has also been observed in different types of tumors, and its
expression has been associated with aggressive tumor progres-
sion and poor patient diagnosis. Nanog-expressing tumors have
been found in a wide variety of tissues, such as breast (Ezeh et
al., 2005; Alldridge et al., 2008), cervix (Ye et al., 2008),
kidney (Bussolati et al., 2008), oral cavity (Chiou et al., 2008),
lung (Chiou et al., 2010), ovary (Zhang et al., 2008), gastric
epithelium (Lin et al., 2012), pancreas (Wen et al., 2010),
colon (Meng et al., 2010), and in germ cells (Gillis et al., 2011).
A report by Jeter et al. analyzed the knockdown of Nanog in
different cancer cell lines and found reduced clonal and
clonogenic growth, reduced proliferation, and altered differ-
entiation potential after Nanog ablation (Jeter et al., 2009).
Although these publications alluded to a functional involve-
ment of Nanog in tumor biology, many papers have reported
that Nanog is confined to the cytoplasm, with no clear
evidence of tumor-inducing functionality. Furthermore, sys-
tematic screens of different pluripotency-related transcription
factors within patient tumor samples have shown that Nanog
expression is not clinically relevant in colorectal cancer (Saiki
et al., 2009). As a result, it remains unclear whether Nanog
has oncogenic properties, in contrast to other transcription
factors including Oct4. In light of these findings, we sought to
clarify the role of Nanog in tumor formation and to this end
generated a Nanog-inducible mouse line to investigate the
tumor initiation potential of Nanog in the adult organism.Material and methods
Plasmid construction
The murine Nanog cDNA was amplified by reverse
transcription-polymerase chain reaction (RT-PCR) from ES
cell cDNA using the primers Nanog_cDNA as shown in Table S1.
The Nanog cDNA was cloned into a pCR2.1-TOPO plasmid
(Invitrogen) and then cloned into a promoter-less pSport1
plasmid containing an SV40 polyadenylation sequence. This
promoter-less plasmid was used to insert the tet-cmv_2-
Insulator_PGK-Hygromycin cassette upstream of Nanog using
Red/ET recombineering (Zhang et al., 1998, 2000).
Cell culture and production of tet-Nanog ES cells
Mouse ES cells were cultured in DMEM-KnockOut (Gibco,
10829018), containing 15% fetal calf serum (FCS; Biowest,
Cat. S1810-500, Lot. S04595S1810), 1× penicillin/strepto-
mycin/glutamine (PAA, P11-013), 1× nonessential amino
acids (PAA, M11-003), and 50 μM 2-mercaptoethanol (Gibco,
31350010) on 0.1% gelatin-coated (Sigma, G1393) plates.
Unless otherwise indicated, medium was supplemented with
1000 units/ml of leukemia inhibitory factor (LIF; home-
made). For the production of the tet-Nanog ES cells, ES cells
carrying the Oct4-GFP transgene from OG2 mice were
used (Yoshimizu et al., 1999; Szabó et al., 2002). The
transactivator CAGGs-irtTA-GBD*-IRES-puro (Anastassiadis
et al., 2010) and the tet-responsive Nanog transgenes
were sequentially electroporated into the cells using the
Nucleofection II device from Amaxa. Electroporation was
performed according to the manufacturer's instructions, and
subsequent selection was performed with puromycin (1 μg/ml;
Sigma P8833) and hygromycin (200 μg/ml; Roth Cp12.2).
Clonal cell lines were established and tested for transgene
induction.
Generation of tet-Nanog mice
ES cells were aggregated and cultured with denuded 8-cell-
stagemouse embryos as described by Nagy and Rossant (Nagy et
al., 2002) with slight modifications. Briefly, 8-cell embryos
were flushed from (C57BL/6 × C3H) F1 female × CD1malemice
at 2.5 days post coitum (dpc) and placed in M2medium (Nagy et
al., 2002). Clumps of 8–15 loosely connected ES cells from
short trypsin-treated day-2 ES cell cultures were chosen and
transferred into small drops of potassium simplex optimized
medium (KSOM medium) (Summers et al., 2000) with 10% FCS
under mineral oil; each clump was placed in a depression in
the drop. Meanwhile, batches of 30–50 embryos were briefly
incubated in acidified Tyrode's solution (Nagy et al., 2002)
until dissolution of their zona pellucida. A single embryo was
placed on each clump of ES cells. All aggregates were
assembled in this manner and cultured overnight at 37 °C,
5% CO2 to allow the ES cells to integrate into the embryos.
Finally, 11–14 aggregates were transferred into the uterine
horns of each 2.5-dpc pseudopregnant foster mother (CD1
female × vasectomized CD1 male mice). The chimeric pups
were delivered by natural birth or Cesarean section at 19.5
dpc and set up with foster mothers. Cells in culture were
induced with 1 μg/ml of doxycycline (Sigma, D9891) and
302 G. Fischedick et al.1 × 10−7 M dexamethasone (Sigma, D1756). Mice were induced
by intraperitoneal injection of 2 mg doxycycline (Sigma, D9891)
and 0.5 mg dexamethasone (Sigma, D1756) or 0.63 mg
dexamethasone-21-isonicotinate (Boehringer Ingelheim) every
other day.Protein and RNA preparation from organ samples
Samples of mouse organs were immediately frozen in liquid
nitrogen after dissection. The organ samples were stored at
−80 °C before being homogenized using the Precellys
24-Dual Homogenizer from Peqlab. Homogenization of the
RNA samples was done in RLT Buffer (QIAGEN) followed by
RNA extraction using the QIAGEN RNeasy Mini Kit. Protein
samples were homogenized in RIPA Buffer (Sigma, R0278) in
the presence of proteinase inhibitors (Roche, 11836153001).
Protein content was measured using the Pierce 660 nm
Protein Assay (Thermo Scientific, 22660).Western blot analysis
Protein samples were boiled in SDS sample buffer and separated
by a 12.5% SDS-PAGE and blotted onto polyvinylidene fluoride
(PVDF) membranes. 25 μg of total protein extract was used per
lane. Primary antibodies were anti-Nanog (1:500 dilution;
Abcam, ab80892) and anti-Gapdh (1:10,000 dilution; Ambion,
4300). Secondary antibodies were anti-rabbit HRP (1:20,000
dilution; GE Healthcare, NA934) and anti-mouse HRP (1:20,000
dilution; Dianova, 115-035-044).Histologic and immunohistochemical analyses
Tissue samples were fixed in 4% paraformaldehyde for
48–72 h at 20 °C. Samples were then dehydrated and
embedded in paraffin. Sections (4 μm) were stained with
hematoxylin and eosin (H&E) or Periodic acid-Schiff (PAS)
for histological analysis. Serial sections were used for
immunohistochemical analysis. Immunostaining was per-
formed on unstained paraffin sections. First, the sections
were deparaffinized and rehydrolyzed using 100% Xylol
followed by a dilution series with isopropanol (100%, 90%,
70%). Antigen retrieval was performed by cooking the slides
in Tris-EDTA buffer for 20 min (10 mM Tris Base, 1 mM EDTA
solution, 0.05% Tween 20, pH 9.0). Blocking was done in a 5%
bovine serum albumin (BSA), 0.1% Triton X-100 PBS solution
for 1 h at room temperature. Primary and secondary
antibodies were incubated at room temperature for 1 h
and 30 min, respectively. BrdU staining required an addi-
tional HCl (4 M) treatment for 20 min. Primary antibodies
were anti-Nanog (1:50 dilution; Abcam, ab80892), anti-Cdx2
(1:100 dilution; Biogenex, CDX2-88), anti-Klf4 (1:100 dilution;
Santa Cruz, sc-20691), anti-β-catenin (1:100 dilution; BD
Transduction Laboratories, 610154), and anti-BrdU (1:100
dilution; Developmental Studies Hybridoma Bank, G3G4).
Secondary antibodies were Alexa Fluor 488 or Alexa Fluor
568 from Invitrogen (1:400 dilution). Slides were mounted
with Vectashield Mounting Medium with Dapi (Vector H-1200)
and analyzed by fluorescence microscopy.BrdU labeling
BrdU (Sigma B5002) was injected intraperitoneally at a
concentration of 30 mg/kg of body weight. Mice were
sacrificed 2, 4, and 48 h after injection, and BrdU incorpo-
ration was detected by immunohistochemistry. Quantifica-
tion of BrdU-positive cells was done using ImageJ.Cell proliferation analysis
NIH 3T3 fibroblasts were cultured on a 12-well dish in a rich
medium containing 10% BSA. 3 × 104 cells were infected with
retroviral vectors expressing mouse Nanog cDNA or empty
control vector. Cells were counted by hand on days 0, 2, 4,
and 7.Epithelial cell preparation
The intestine and colon were isolated from induced and
uninduced tet-Nanog mice. The organs were washed with
PBS and incised along their length. Samples were then
incubated with PBS/EDTA (5 mM) at 4 °C for 30 min,
followed by vigorous shaking and centrifugation at 500 rpm
for 5 min. Pellets were resuspended in 0.25% trypsin/EDTA
supplemented with 0.8 μg/μl DNase and incubated at 37 °C
for 30 min. After digestion, samples were shaken and
centrifuged at 1400 rpm for 10 min. Pellets were resuspend-
ed in DMEM Low Glucose medium and filtered twice through
a 100-μm cell strainer and then twice through a 70-μm cell
strainer. Single cells were obtained and used for follow-up
experiments.Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described (Marson et al.,
2008) with some modifications. Intestinal and colonic epithe-
lial cells were cross-linked with 1% formaldehyde for 10 min at
room temperature, and chromatin was digested with micro-
coccal nuclease followed by 10 × 30-s pulses of sonication
using Biorupter (Diagenode). Chromatin fragments, mainly
mono- to trinucleosome in size, were immunoprecipitated
with the antibodies against Nanog (A300-397A, Bethyl
Laboratories) or normal rabbit IgG. The precipitated DNA
was analyzed by using real-time PCR. For each experiment,
the percentage of input was determined and normalized to
the value obtained at two negative control regions within the
intergenic spacer (IGS) of ribosomal DNA. All primers are listed
in Table S1.Quantitative real-time PCR
Reverse transcription was performed using the MMLV reverse
transcriptase (USB) and Oligo-dT15 priming at 42 °C for 1 h
followed by 60 °C heat inactivation for 10 min. A cDNA
concentration equivalent to 50 ng of total RNA was used for
the real-time polymerase chain reaction (PCR). Real-time
PCR was performed with 2× Power SYBR Green PCR mix (ABI)
and 0.375 μM of each primer in a total volume of 20 μl using
the ABI 7300 cycler. Calculations were done using the ΔΔCt
303Nanog induces hyperplasia without initiating tumorsmethod with two housekeeping genes as internal controls.
The primers used are listed in Table S1.
Microarray analysis
RNA samples for the microarrays were prepared using QIAGEN
RNeasy columnswith on-column DNA digestion. 300 ng of total
RNA per sample was used as input into a linear amplification
protocol (Ambion), which involved synthesis of T7-linked
double-stranded cDNA and 12 h of in vitro transcription
incorporating biotin-labeled nucleotides. Purified and labeled
cRNA was hybridized for 18 h onto MouseRef-8 v2 expression
BeadChips (Illumina) following the manufacturer's instruc-
tions. After washing as recommended, the chips were stained
with streptavidin-Cy3 (GE Healthcare) and scanned using the
iScan reader (Illumina) and accompanying software. Samples
were exclusively hybridized as biological replicates. The bead
intensities weremapped to gene information using BeadStudio
3.2 (Illumina). Background correction was performed using the
Affymetrix Robust Multi-array Analysis (RMA) background
correction model (Irizarry et al., 2003). Variance stabilization
was performed using the log2 scaling, and gene expression
normalization was calculated with the method implemented
in the lumi package of R-Bioconductor. Data post-processing
and graphics was performed with in-house developed func-
tions in Matlab. Hierarchical clustering of genes and samples
was performed with one minus correlation metric and the
unweighted average distance (UPGMA) (also known as group
average) linkage method.
Flow cytometry
Cells then were stained with purified anti-mouse CD326 (Clone
G8.8, eBioscience) and APC-conjugated donkey anti-rat sec-
ondary antibody (Jackson ImmunoResearch) and analyzed on a
FACSAria cell sorter (BD Biosciences). Highly CD326-positive
cells were isolated by fluorescence-activated cell sorting (FACS)
using a 100-μm nozzle. Data analysis was done using FlowJo
software (Tree Star).
Results
Generation of Nanog-inducible transgenic mice
Murine ES cells derived from mice of OG2 background
were used to engineer Nanog-inducible ES cells. These
ES cells carry an Oct4-GFP reporter construct, whose
expression corresponds to that of the endogenous Oct4
and which is a valid reprogramming marker according to
our previous studies (Boiani et al., 2002; Do and Schöler,
2004; Kim et al., 2008, 2009). A modified tetracycline-
inducible system, first described by Anastassiadis et al.
(2002) was used to drive inducible expression of the Nanog
transgene (Fig. 1A) upon the addition of doxycycline
and dexamethasone (Fig. S1 available online). A clonally
derived Nanog-inducible ES cell line showed strong and
rapid induction of the Nanog transgene after addition
of dexamethasone and doxycycline (Fig. 1B). Using quan-
titative real-time PCR, full expression of the Nanog
transgene was detected 3.5 h after induction. Accordingto previous publications, induced tet-Nanog ES cells can be
grown indefinitely in the absence of LIF (Chambers et al.,
2003; Mitsui et al., 2003). The Oct4-GFP transgene, an
indicator of pluripotency, remained highly active, and cells
obtained a normal ES cell morphology when seeded back on
a layer of irradiated mouse embryonic fibroblasts without
LIF supplementation (Fig. 1C). This result indicated that
the Nanog transgene was biologically functional. Trans-
genic mice were produced from this ES cell line by diploid
morula aggregation and subsequent mating. Following
intraperitoneal injection of doxycycline and dexametha-
sone, strong transgene induction was detected in nearly all
major organs (Figs. 1D and E). The low induction level in the
brain may be due to the difficulty of the ligands in passing
through the blood–brain barrier, as previously observed
in other tet-inducible mouse models (Hochedlinger et al.,
2005; Anastassiadis et al., 2010). Interestingly, after
induction with doxycycline and dexamethasone, Nanog
expression levels in most organs exceeded those of wild-type
ES cells (Fig. S1B).Nanog expression leads to hyperplasia in the intestinal
and colonic epithelium
To force Nanog expression, 3- to 6-week-old mice were
injected intraperitoneally with doxycycline and dexametha-
sone every other day. Depending on the age, mice reacted
well to treatment for up to 6 weeks, after which they became
morbid and died. An initial screen of old mice treated for
6 weeks revealed that morphological changes were restricted
to the intestinal tract. As shown in Fig. 2A, these mice showed
significant extensions of the villi in the small intestine and
outgrowths of themucosa in the colon. These protrusionswere
examined pathologically and diagnosed as hyperplasia of the
intestinal epithelium. Control mice carrying the irtTA did not
show phenotypic changes of the intestinal tract after
prolonged injection with doxycycline and dexamethasone.
To further study the onset of the phenotype, 3-week-old mice
were used for follow-up experiments. If Nanog interfered with
the development of the gut epithelium, the young mice were
expected to show a stronger or an earlier onset of the
phenotype. As the young mice died within 3 weeks of
treatment, the timeframe of the experiment was shortened
to 2.5 weeks. Through quantification of villus length, we
identified that the elongation of the villi was most significant
in the duodenum and jejunum (Fig. 2B). After 7 days of Nanog
induction, the villi had extended by almost 100% in the
duodenum and jejunum, with no significant change in villus
length in the ileum. This phenotypic effect became more
prominent until day 9, after which time there was no
significant change in villus length. Interestingly, the pheno-
type was reversible following termination of Nanog induction.
Three weeks after Nanog withdrawal, the length of the villi
was significantly reduced, approaching baseline levels of
control mice. This shows that the observed extension was
dependent upon continuous Nanog expression. The colon also
showed signs of hyperplasia 9 days after induction (Fig. 2C). In
the cecum, small outgrowths from the epithelial layer had
started to form, consistent with the outgrowths we observed
in the older mice that had been treated for 6 weeks. In
comparison, the mucosa of the uninduced cecum was much
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Figure 1 Characterization of Nanog-inducible mouse embryonic stem cells and mice. (A) Schematic overview of the transgenes used to
produce the Nanog-inducible ES cells and mice. Both transgenes were randomly integrated into OG-2ES cells. An improved codon-optimized
tetracycline transactivator fused to the glucocorticoid receptor ligand-binding domainwas used. TheNanog transgene is under the control of a
tetracycline-responsive CMV minimal promoter protected by two chicken beta globin insulators. The arrowheads mark the transcriptional
start sites. irtTA, improved reverse tetracycline transactivator; VP16, viral protein 16; GBD, mutated glucocorticoid receptor ligand-binding
domain; IRES, internal ribosomal entry site; pA, polyadenylation signal; Ins, chicken beta globin insulators. (B) Kinetics of Nanog transgene
response to doxycycline and dexamethasone induction in ES cells. Nanog RNA levels were measured using quantitative real-time PCR, with
levels normalized to those obtained using uninduced tet-Nanog ES cells. (C) Cultivation of tet-Nanog ES cells in the absence of LIF with and
without the induction of Nanog transgene. GFP signal is representative of the endogenous Oct4 levels. (D) RNA levels of the Nanog transgene in
different organs of tet-Nanogmice after intraperitoneal injection of dexamethasone and doxycycline. Levels in induced organs are normalized
to those of in uninduced organs. (E) Western blot analysis of tet-Nanogmouse after Nanog transgene induction. + and − represent the induced
state and the uninduced state, respectively. The bars in panels B and D reflect normalization errors. The scale bars in panel C are 100 μm.
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305Nanog induces hyperplasia without initiating tumorssmoother and looked more structured. PAS staining also
revealed an underrepresentation of goblet cells within these
outgrowths; however, this did not affect the total amount of
goblet cells in the small intestine and colon (Fig. S3B). In
the colon, the typical smooth colonic epithelium had become
more ridged and had begun growing further into the lumen. As
in the cecum, PAS staining of the colon showed a reduction in
the amount of goblet cells within these outgrowths (Fig. 2C).
Increased proliferation rates in the crypt compartment
causes hyperplasia in Nanog-induced mice
Several studies have shown that Nanog has an accelerating
effect on the cell cycle, so we performed a proliferation assay
on NIH 3T3 cells infected with Nanog to validate this (Zhang et
al., 2005, 2009; Camp et al., 2009). Our results are consistent
with previously published data, showing an enhanced rate of
proliferation of NIH 3T3 cells infected with Nanog (Fig. 3A)
(Zhang et al., 2005). Next, a BrdU staining of the small intestine
and colon was performed to test the effect of Nanog on
proliferation in vivo. An initial screen was performed on mice
induced for 9 days with a 4-h BrdU pulse. Although the staining
signal appeared stronger in Nanog-induced mice, no change in
the location of the proliferating cells was revealed. All
BrdU-positive cells were located in the crypt compartment
(Fig. 3B). To further investigate the behavior of the proliferat-
ing cells, a time course of BrdU incorporation was performed.
Micewere inducedwith Nanog for 7 days and then injectedwith
BrdU. At different time points after the injection, BrdU
incorporation was analyzed. Two hours after BrdU injection,
stronger staining was observed within the crypt compartment
of the Nanog-induced mice compared with the uninduced
mice (Fig. 3C). Quantification revealed an 85% increase in
BrdU-positive cells per crypt compared with control mice
(Fig. 3C). This showed that ectopic Nanog expression influences
the proliferation of naturally proliferating cells in the crypt
compartment. To determine whether this corresponds to a
faster repopulation of the villi in Nanog-induced mice, we
examined BrdU incorporation at 48 h. In Nanog-induced mice,
BrdU-stained cells hadmigrated to the top of the villus, while in
control mice, the BrdU-stained cells had migrated only midway
up the villi (Fig. 3D). Taken together, these results show that an
increased proliferation of the crypt compartment correlates
with an increased repopulation of the villi, suggesting that
increased proliferation is a key component of the observed
hyperplasia in Nanog-induced mice.
Ectopic Nanog expression leads to differential
expression of genes in intestine and colon
To gain further insight into these changes on a molecular
level, a global gene expression analysis was performed.
Tissue samples exhibited heterogeneity, as observed by
principal component analysis, with repeats of the small
intestine in particular not clustering as well as the ones from
the colon (Fig. 4E). Thus, it is possible that only changes in
widely expressed genes could be picked up in our experi-
ments. The scatter plot showed that Nanog expression led to
416 differentially expressed genes in the small intestine
(Fig. 4C) and 408 in the colon (Fig. 4D). Some commonly up-
and downregulated genes in both organs were identified,among them the key intestinal regulators Cdx2 and Klf4
(Figs. 4A–D). Both of these genes have been described to
be tumor suppressors and are involved in the control of
differentiation and growth of the intestinal epithelium
(Garrett-Sinha et al., 1996; Shields et al., 1996; Beck et
al., 1999; Katz et al., 2002; Bonhomme et al., 2003;
McConnell et al., 2007; Gao et al., 2009). As a result, both
Cdx2 and Klf4 are very interesting candidates for further
investigations. To address the issue of heterogeneity in the
whole tissue samples, an additional microarray on presorted
intestinal and colonic epithelial cells was performed. As
expected, the dendrogram of the sorted repeats showed a
much higher degree of homogeneity compared with the
whole tissue sample (Fig. S4A). However, as no additional
candidate genes were found, the focus was on Cdx2 and Klf4
(Figs. S4B–D).
Nanog crosstalks with Cdx2 and Klf4 in the intestinal
tract of mice
We evaluated Cdx2 repression with a Nanog overexpression
time course, quantified by real-time PCR. Downregulation of
Cdx2 in the small intestine and colon was observed throughout
the entire 3-week time course (Figs. 5A and C). After
2–3 weeks of treatment, expression of Cdx2 was reduced to
about 20% of its original level in the small intestine and down
to 1% in the colon. In response to Nanog induction,
downregulation of Klf4 expression followed the same trend,
but was not as strong (Fig. S2). To determine whether the
observed Cdx2 downregulation is a direct effect of Nanog
expression, an expression profile was performed for the 12 h
following Nanog induction. Cdx2 expression negatively corre-
lated with Nanog expression (Figs. 5B and D), as both the small
intestine and the colon showed a strong downregulation of
Cdx2 within the first 6 h of Nanog expression (Figs. 5B and D).
This effect was stronger in the colon, correlating with the
findings of the microarray analysis and the 3-week real-time
PCR time course (Figs. 4B, 5A, and C). Within the first 6 h of
Nanog induction, a rapid and immediate downregulation in
Klf4 expression was also observed. The degree of repression
was similar in both the small intestine and colon (Figs. S3B and
D). Next, double immunostaining was performed for Cdx2 and
Nanog on treated versus untreated samples. The negative ex-
pression of Cdx2 in the epithelium of the small intestine
was found to correlate with the strong Nanog expression
throughout the entire villus (Fig. 5E). A strong reduction in
Cdx2 protein was also found in the colon (Fig. 5E). However, as
Nanog expression was not as uniform as in the small intestine,
some cells remained positive for Cdx2. Repression of Cdx2
correlated with Nanog expression, as only cells that stained
highly positive for Nanog were negative for Cdx2 (Fig. 5E). This
further confirmed the strong dependence of Cdx2 expression
levels on the presence of Nanog.
Nanog occupies Cdx2 and Klf4 regulatory elements
in intestine and colon
To clarify whether the observed downregulation of Cdx2 and
Klf4 in response to Nanog induction is a direct or an indirect
effect, chromatin immunoprecipitation (ChIP) of Nanog was
performed on primary intestinal and colonic epithelial cells.
Induced InducedUninduced Uninduced
Cecum Colon
H&E
H&E
PAS
A BInducedUninduced
In
te
st
in
e
Co
lo
n
C
0
100
200
300
400
500
600
700
800
DuodenumJejunumIleum
R
el
at
iv
e 
Vi
lli
 L
en
gt
h
0 Days 7 Days 9 Days 17 Days Withdrawal
Figure 2 Histological analysis of hyperplasia in Nanog-induced mice. (A) H&E staining of the small intestine and colon after 6 weeks
of Nanog induction. Hyperplasia is observed in the epithelium of the small intestine and colon, manifesting as an extension of the villi
in the small intestine and villi-like outgrowths of the colonic epithelium into the lumen of the colon. (B) The length of the villi of the
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306 G. Fischedick et al.A previous transgenic study identified an enhancer located
8.5-kb upstream of the transcriptional start site that directs
the expression of Cdx2 in intestinal cells (Benahmed et al.,2008). Interestingly, Nanog binds to the promoter (Region C)
and upstream enhancer (Region A) of Cdx2 in both the small
intestine and colon (Figs. 6B and D). Strong binding of Nanog
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Figure 3 Effects of Nanog expression on proliferation in vitro and in vivo. (A) Proliferation curve of Nanog-expressing NIH 3T3 cells,
compared with wild-type NIH 3T3 cells. (B) BrdU immunostaining of the small intestine and colon after a 4-h BrdU pulse. tet-Nanog
mice induced for 9 days were compared with uninduced mice. (C) Analysis of BrdU incorporation after a 2-h BrdU pulse 7 days after of
Nanog induction. The left panel shows a quantification of the BrdU-positive cell per crypt of each villus (control, n = 647; Nanog
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show immunostaining of a 48-h BrdU pulse. The left-hand side shows uninduced control images; the right-hand side shows images of
mice induced with Nanog for 7 days. The scale bars in panels B, C, and D are 50 μm.
307Nanog induces hyperplasia without initiating tumorswas also observed downstream of Cdx2 (Region G), corre-
sponding to a potential enhancer region identified in mouse
(Watts et al., 2011) and human (Watts et al., 2011) The first
intron (Regions D and E), which is occupied by Nanog in ES
cells (Chen et al., 2008), also showed significant binding
in both the small intestine and colon, suggesting that a
common regulatory mechanism is active in these cells (Chen
et al., 2009). Nanog also binds to the promoter region
(Regions B and C) and upstream conserved region (Region A)
of Klf4 in both the small intestine and colon (Figs. 7B and D).
In contrast, the promoter region of β-catenin, which is
highly expressed but not affected by Nanog induction,
showed no enrichment, confirming the specific binding of
Nanog to Cdx2 and Klf4 (Figs. 6C, E, 7C, and E).
Nanog does not effect the Wnt pathway in
intestinal epithelium
The Wnt pathway plays an important role in the develop-
ment of a normal and functional intestinal epithelium.Strong Wnt activation is often observed in intestinal tumors
and has been reported to mediate for the phenotype
observed after Oct4 induction (Hochedlinger et al., 2005).
However, our microarray analysis did not reveal a strong
upregulation of Wnt downstream target genes, such as
CyclinD1 and c-Myc. As an active Wnt pathway can be
identified by the nuclear localization of β-catenin, we then
performed double immunostaining for Nanog and β-catenin.
As shown in Fig. 5F, Nanog did not cause translocation of
β-catenin into the nucleus of epithelial cells in the colon and
small intestine. This finding demonstrates that Nanog does
not affect the activity of the Wnt pathway, excluding a
contribution of Wnt to the observed phenotype.Discussion
We have generated and characterized a Nanog-inducible
mouse with high Nanog expression levels in most major
organs. Contrary to what we expected, prolonged Nanog
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Figure 4 Global gene expression comparison for small intestine and colon after Nanog induction. (A) Heatmap of upregulated genes common to both the small intestine and colon
after Nanog induction. Int−, uninduced small intestine; Int+, induced small intestine; Col−, uninduced colon; Col+, induced colon. (B) Heatmap of downregulated genes common to
both the small intestine and colon after Nanog induction. Int−, uninduced small intestine; Int+, induced small intestine; Col−, uninduced colon; Col+, induced colon. (C) Pairwise
scatter plot of uninduced vs Nanog-induced small intestine. Int−, uninduced small intestine; Int+, induced small intestine. The Nanogpd probe corresponds to the tet-Nanog
transgenes, and the Nanog probe to the endogenous Nanog gene. (D) Pairwise scatter plot of uninduced vs Nanog-induced colon. Col−, uninduced colon; Col+, induced colon. The
Nanogpd probe corresponds to the tet-Nanog transgenes, and the Nanog probe to the endogenous Nanog gene. (E) Principal component analysis of microarray data. The 1st principal
component (PC1) captures 44% of the gene expression variability and the 2nd principal component (PC2) captures 17% of the variability. Panels A through D represent gene expression
levels in a log2 scale.
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Figure 5 Effect of ectopic Nanog expression on Cdx2 and β-catenin. (A) Quantitative real-time PCR analysis of Cdx2 levels in the small intestine in a 3-week time course of Nanog
overexpression. (B) Immediate effects of Nanog expression on Cdx2 expression levels in the small intestine, quantified via real-time PCR analysis. (C) Quantitative real-time PCR
analysis of Cdx2 levels in the colon in a 3-week time course of Nanog overexpression. (D) Immediate effects of Nanog expression on Cdx2 expression levels in the colon, quantified via
real-time PCR analysis. (E) Immunostaining for Cdx2 after 9 days of Nanog overexpression in the small intestine and colon. (F) Immunostaining for β-catenin after 9 days of Nanog
overexpression in the small intestine and colon. The bars in panels A through D represent the normalization error. The scale bars in panels E and F are 50 μm.
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310 G. Fischedick et al.expression led to phenotypic changes that were restricted to
the small intestine and colon, leaving other major organs
unaffected. Although Nanog does not play a role in theformation of the gastrointestinal tract during embryonic
development, its overexpression during adulthood leads to
hyperplasia of the epithelium and abnormal morphology of
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312 G. Fischedick et al.the mucosal architecture (Fig. 2A). Hyperplastic outgrowths
were always observed but they never led to the formation of
adenomas or carcinomas. To gauge whether mice that had
not reached adulthood would show a stronger response to
Nanog expression, newly weaned 3-week-old mice were
analyzed. Though these mice were not able to withstand the
treatment for longer than 2–3 weeks, they showed signs of
hyperplasia after only 7 days. The villi of the small intestine
doubled in length on day 7 and continued to grow until day 9,
after which time the extension leveled off. Three weeks
after withdrawal of dexamethasone and doxycycline, down-
regulation of Nanog expression and reduced villus length
were once again observed, showing that the hyperplasia is
dependent upon continuous Nanog expression (Fig. 2B). The
colon also showed signs of hyperplasia after 9 days of Nanog
induction. As shown in Fig. 2C, the colonic mucosa, which
has a typical flat morphology, developed outgrowths that
were pathologically identified as hyperplasia of the colonic
epithelium. Moreover, a reduction in the number of goblet
cells within these outgrowths was observed by PAS staining.
Forced expression of Nanog in NIH 3T3 cells and human ES
cells has been shown to promote entry into the S-phase of
the cell cycle, enhancing the rate of proliferation (Zhang et
al., 2005, 2009). To determine whether Nanog influences
the proliferation of the intestinal tract, a time course of
BrdU incorporation was performed after 7 days of Nanog
overexpression. Indeed, 2 h after BrdU administration, an
additional 85% of cells in the crypts showed proliferation in
response to Nanog treatment (Fig. 3C). This is an interesting
finding, as the intestinal stem cells residing in the crypts are
responsible for the repopulation of the villi with differenti-
ated cells. The next time point, 48 h post–BrdU administra-
tion, further showed that cells labeled with BrdU migrated
faster up the crypt compartment in the Nanog-induced mice.
The possibility that the observed signal was due to dormant
epithelial cells that had initiated proliferation was exclud-
ed, as the BrdU-labeled cells were not scattered around the
villi but were all in line with the natural migration pathway
from the crypt up the villi. Furthermore, no proliferation of
the typically dormant cells was observed between 2 and 48 h
(see representative example in Fig. 3B). These results
clearly demonstrated that altered proliferation within the
crypt compartment plays a dominant role in the develop-
ment of the observed hyperplasia. The morbidity and deaths
of 6-week-old mice upon Nanog induction might be caused
by a combination of doxycycline/dexamethasone/ethanol
treatment and malabsorption related to the intestinal
phenotype.
By microarray analysis and subsequent immunostaining,
significant downregulation of both Cdx2 and Klf4 was
observed in the small intestine and colon. Both genes play
an important role in the development and maintenance of a
functional intestinal epithelium. The finding that other
organs did not exhibit phenotypic changes upon Nanog
overexpression suggested that Cdx2 and Klf4 might be key
factors in the development of the described phenotype.
Using quantitative real-time PCR, a strong reduction of
Cdx2 and Klf4 expression levels was found within the first 6 h
of Nanog induction, demonstrating that Nanog is a direct
repressor of these two genes (Figs. 5A–D and S2). ChIP further
revealed binding of Nanog to the regulatory elements of Cdx2
and Klf4 in primary cells isolated from the small intestineand colon (Figs. 6 and 7). These results, together with the
expression data, clearly demonstrate that Nanog binds to Cdx2
and Klf4 and represses their transcription.
Cdx2 is a transcription factor that regulates numerous
intestine-specific genes and mediates many cellular processes,
such as cell differentiation, proliferation, adhesion, migration,
and tumorigenesis (Ee et al., 1995; Chawengsaksophak et al.,
1997; Beck et al., 1999, 2003; Aoki et al., 2003; Bonhomme et
al., 2003; Gao et al., 2009). During early embryonic develop-
ment, Cdx2 expression is repressed by Nanog and restricted to
the extraembryonic lineage (Chen et al., 2009). The down-
regulation of Cdx2 in the Nanog-expressing intestinal epithe-
lium clearly demonstrates that Nanog suppression of Cdx2 is
conserved from embryonic development to adulthood. A Cdx2
homozygous knockout phenotype is lethal, whereas heterozy-
gous mice spontaneously form adenomatous polyps, particu-
larly in the proximal colon, correlating with the appearance
of the epithelial outgrowths we identified after Nanog
induction (Chawengsaksophak et al., 1997). The adenomas in
the heterozygous knockout mice were shown to be negative
for Cdx2, and mouse chimeric models and conditional Cdx2
knockout models have further strengthened the validity of
these findings (Beck et al., 2003; Gao et al., 2009).
The downregulation of Klf4 is another interesting effect
of Nanog overexpression. Klf4 has also been shown to act as
a tumor suppressor and its absence to lead to induction of
hyperplasia in the gastric epithelium (Katz et al., 2005).
Nanog binding to the Klf4 promoter was demonstrated by
ChIP analysis, revealing that Nanog itself exerts a repressive
action upon Klf4. Furthermore, Cdx2 has been shown to be
an activator of Klf4 (Mahatan et al., 1999; Dang et al., 2001),
suggesting that Nanog likely affects Klf4 expression directly
by binding to the Klf4 promoter and indirectly by suppressing
Cdx2 expression.
Our in vivo study of Nanog overexpression identified the
transcription factor to be an inducer of hyperplasia and a
repressor of both Cdx2 and Klf4 expression in the adult
intestinal epithelium. Although Cdx2 and Klf4 expression has
been previously associated with hyperplasia and adenoma
formation, we could not find evidence that it leads to tumor
formation in our mice. As mice heterozygous for Cdx2 form
adenomatous polyps at 3 months of age (Chawengsaksophak
et al., 1997), it is possible that the timeframe of our
experiments was too short to observe initiation of tumor
growth. However, unlike Oct4, Nanog does not affect the
Wnt pathway (Hochedlinger et al., 2005), further reducing
the possibility that Nanog exhibits oncogenic properties and
induces intestinal and/or colonic tumor formation. In line
with our findings a recent study of a NanogP8 homolog
transgenic mouse model demonstrated absence of sponta-
neous tumor formation and actual inhibition of tumor
development in a two-stage chemical carcinogenesis model
(Badeaux et al., 2013).
Taken together, the findings of this study suggest that
Nanog has an influence on the intestinal and colonic
architecture but does not have a functional role in tumor
initiation. However, due to the increased proliferation of
intestinal cells and the repressive effect on both Cdx2 and
Klf4, Nanog may further enhance growth of established
intestinal tumors. The fact that, despite being widely
expressed by the inducible tet-system, phenotypic alter-
ations were only observed in the intestine and colon, argues
313Nanog induces hyperplasia without initiating tumorsagainst Nanog's functional involvement in initiation of tumor
formation in many different tissues. We therefore conclude
that Nanog cannot be classified as an oncogene and that
positive detection of Nanog expression in tumor samples may
be due to secondary events.
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